Rsv Vaccine, Pref A-Pref B, Recombinant Dosage

Medically reviewed by Drugs.com. Last updated on Nov 12, 2024.

Usual Adult Dose for Respiratory Syncytial Virus Prophylaxis

0.5 mL IM as a single dose

Uses:

• For active immunization of pregnant patients at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months of age
• For active immunization for the prevention of LRTD caused by RSV in patients 18 through 59 years of age at increased risk for LRTD caused by RSV

Usual Geriatric Dose for Respiratory Syncytial Virus Prophylaxis

60 years and older: 0.5 mL IM as a single dose

Use: For active immunization for the prevention of LRTD caused by RSV

Usual Pediatric Dose for Respiratory Syncytial Virus Prophylaxis

Pregnant patients at least 10 years of age: 0.5 mL IM as a single dose

Use: For active immunization of pregnant patients at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• History of a severe allergic reaction (e.g., anaphylaxis) to the active component or any of the ingredients

Safety and efficacy to prevent RSV LRTD and severe RSV LRTD in infants born to patients vaccinated at younger than 10 years of age have not been established.
Safety and efficacy to prevent RSV LRTD via active immunization have not been established in nonpregnant patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For IM injection

Storage requirements:

• Before reconstitution: Store refrigerated at 2C to 8C (36F to 46F) in original carton; do not freeze.
• Discard if carton has been frozen.
• After reconstitution: If not administered immediately, store at room temperature (15C to 30C [59F to 86F]) and use within 4 hours; do not freeze.
• Discard if not used within 4 hours.

Reconstitution/preparation techniques:

• Reconstitute the lyophilized antigen component with the sterile water diluent component before administration; do not shake.
• The manufacturer product information should be consulted.

General:

• After reconstitution, a single dose of this drug is formulated to contain 120 mcg of RSV stabilized prefusion F (preF) proteins (60 mcg RSV preF A and 60 mcg RSV preF B) per 0.5 mL.
• This drug is supplied in 3 presentations: Act-O-Vial, vial and prefilled syringe, and vial and vial presentations; the manufacturer product information should be consulted for more information.

Patient advice:

• Read the Vaccine Information Statement (VIS) provided or available from the US CDC (www.cdc.gov/vaccines/hcp/current-vis).
• Report any adverse events to your health care provider or as directed.
• A pregnancy exposure registry is available; if you received this drug during pregnancy, contact (or have your health care provider contact) 1-800-616-3791 to enroll in or obtain information about the registry.

Frequently asked questions

• What is the difference between Arexvy and Abrysvo?
• What are the symptoms of RSV(respiratory syncytial virus)

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer